Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06454175
Status:
RECRUITING
Last Update Posted:
2024-06-12
First Post:
2024-06-06
Brief Title:
A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years
Sponsor:
Shanghai Bovax Biotechnology Co Ltd
Organization:
Shanghai Bovax Biotechnology Co Ltd
Study Overview
Official Title:
A Randomised Double-blind Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of 15-valent Human Papillomavirus Recombinant Vaccine Hansenulapolymorpha in Healthy Chinese People Aged 18-45 Years
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety and tolerability of 15-valent HPV vaccine in 9-45year-old participants
Detailed Description:
A phase 1 random double blind placebo control trail was plan to conducted in 72 healthy participants in the 2 age groups18-45 years old and 9-17 years old The 72 subjects to be inoculated with middle and high dose vaccine first in sequence if there was no safety issue
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None